ATAI AtaiBeckley Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ATAI Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$4.15
Analyst Target
$12.27
+195.7%
Upside
52W High
$6.75
52W Low
$1.15
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$1.51B
P/E
N/A
ROE
-100.8%
Profit margin
N/A
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
ATAI exhibits extremely weak fundamental health with a Piotroski F-Score of just 1/9, indicating severe financial distress. Despite explosive revenue growth of 1772.5% YoY and strong gross margins, the company is deeply unprofitable with negative operating margins (-3796.53%), negative ROE (-100.78%), and deteriorating earnings trends. Valuation metrics are stretched with a Price/Sales ratio of 499.45, while insider selling and poor earnings surprise history further undermine confidence. Although analysts maintain a 'strong_buy' consensus with a $12.27 target, the stock appears highly speculative and financially fragile.
Key Strengths
Exceptional year-over-year revenue growth of 1772.50%, far exceeding sector average of 22.89%
High gross margin of 83.86%, indicating strong pricing power or low production costs
Exceptionally low debt/equity ratio of 0.03, suggesting minimal leverage risk
Strong liquidity position with current ratio of 7.90 and quick ratio of 6.99
Analyst consensus is 'strong_buy' with 11 analysts supporting upside potential
Key Risks
Critically low Piotroski F-Score of 1/9, signaling severe financial weakness and high risk of operational failure
Massive negative operating margin of -3796.53%, indicating unsustainable cost structure
Price/Sales ratio of 499.45 is extremely elevated, suggesting extreme overvaluation relative to sales
Consistent earnings misses: only 1 out of last 4 quarters beat estimates, with an average surprise of -42.31%
Insider selling activity: $0.15M in sales with no offsetting buys in the last 6 months
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
15
68
28
10
0
AI Verdict
Highly speculative with severe financial health concerns outweighing growth potential
Key drivers: Piotroski F-Score of 1/9, Negative operating margin exceeding -3000%, Extreme valuation multiples, Analyst target implies 195% upside, conflicting with fundamentals, Insider selling and poor earnings track record
Confidence
80%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- Price/Sales of 499.45 is extremely high
- Forward P/E of -8.51 indicates negative earnings
- Price/Book of 6.25 is elevated for a loss-making company
- No Graham Number or Intrinsic Value available due to unprofitability
Future
68/100
Ref Growth rates
Positives
- Revenue growth YoY of 1772.50% is exceptional
- Analyst target price implies strong future expectations
Watchpoints
- Earnings growth YoY is -75.0%, showing deterioration
- Most recent Q/Q EPS growth is -100.0%
- Forward P/E negative, signaling no near-term profitability
Past
28/100
Ref Historical trends
Positives
- Some quarters showed positive earnings surprises (e.g., +226.6% in 2023-11-14)
Watchpoints
- 15 out of 19 quarters missed or barely met estimates
- Average earnings surprise over last 4 quarters is -42.31%
- Historical EPS trend shows deepening losses
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity ratio of 0.03 is very low
- Current ratio of 7.90 and quick ratio of 6.99 indicate strong liquidity
Watchpoints
- Piotroski F-Score of 1/9 indicates critical financial weakness
- ROE of -100.78% and ROA of -29.25% show severe unprofitability
- Operating margin of -3796.53% is unsustainable
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
- No indication of future dividend plans
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.15
Analyst Target
$12.27
Upside/Downside
+195.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ATAI and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ATAI
AtaiBeckley Inc.
Primary
|
-78.7% | +117.3% | +174.8% | +16.2% | -0.9% | +14.0% |
|
AXGN
Axogen, Inc.
Peer
|
+76.4% | +203.1% | +75.6% | +145.6% | +0.6% | +5.8% |
|
AHCO
AdaptHealth Corp.
Peer
|
-72.3% | -20.2% | +10.2% | +14.1% | +0.5% | +11.6% |
|
ANIP
ANI Pharmaceuticals, Inc.
Peer
|
+113.5% | +73.9% | +14.7% | -27.9% | -7.5% | -4.8% |
|
BCRX
BioCryst Pharmaceuticals, Inc.
Peer
|
-25.9% | -38.3% | -12.2% | -20.6% | -11.8% | +1.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-8.51
PEG Ratio
N/A
P/B Ratio
6.25
P/S Ratio
499.45
EV/Revenue
463.3
EV/EBITDA
-13.79
Market Cap
$1.51B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-3796.53%
Gross Margin
83.86%
ROE
-100.78%
ROA
-29.25%
Growth
Revenue and earnings growth rates
Revenue Growth
+1772.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
7.9
Strong
Quick Ratio
6.99
Excellent
Cash/Share
$0.32
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-16
$N/A
2025-11-12
$-0.28
-125.3% surprise
2025-08-14
$-0.14
-18.3% surprise
2025-05-14
$-0.15
+16.7% surprise
Healthcare Sector Comparison
Comparing ATAI against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-100.78%
This Stock
vs
-52.77%
Sector Avg
+91.0%
(Excellent)
Debt to Equity
0.03
This Stock
vs
6.16
Sector Avg
-99.4%
(Less Debt)
Revenue Growth
1772.5%
This Stock
vs
137.39%
Sector Avg
+1190.1%
(Fast Growth)
Current Ratio
7.9
This Stock
vs
3.36
Sector Avg
+135.1%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ATAI
AtaiBeckley Inc.
|
BEARISH | $1.51B | - | -100.8% | -% | $4.15 | |
|
AXGN
Axogen, Inc.
|
NEUTRAL | $1.51B | - | -1.9% | -1.0% | $32.83 | |
|
AHCO
AdaptHealth Corp.
|
BEARISH | $1.44B | - | -4.3% | -2.2% | $10.6 | |
|
ANIP
ANI Pharmaceuticals, Inc.
|
BEARISH | $1.58B | 21.23 | 16.2% | 8.9% | $70.49 | |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
NEUTRAL | $1.43B | - | -% | -1.5% | $6.79 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-02 | FEILDING-MELLEN COSMO | Director | Sale | 39,594 | $154,377 |
| 2025-11-05 | FEILDING-MELLEN COSMO | Director | Stock Award | 7,702,990 | - |
| 2025-09-30 | APEIRON INVESTMENT GROUP LTD. | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 2,367,200 | - |
| 2025-08-14 | APEIRON INVESTMENT GROUP LTD. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 8,675,799 | $19,000,000 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
11 analysts
Guggenheim
2026-01-20
Buy
Jones Trading
2025-12-23
Buy
Canaccord Genuity
2025-10-22
Buy
Buy
Needham
2025-10-13
Buy
HC Wainwright & Co.
2025-09-23
Buy
Buy
HC Wainwright & Co.
2025-07-30
Buy
Buy
Oppenheimer
2025-07-29
Outperform
Canaccord Genuity
2025-07-28
Buy
Buy
Past News Coverage
Recent headlines mentioning ATAI from our newsroom.
Newest → oldest
No matching news yet.